JCO precision oncologyHumansMaleFemaleRetrospective StudiesAdenocarcinoma
Immune Checkpoint Inhibitors for Mismatch Repair-Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo Clinic.
Oudai Sahwan, Fares Jamal, Rish Pai, Cody Eslinger, Shaylene McCue, Mitesh Borad, Mojun Zhu, Priya Pai, Hao Xie, Robert McWilliams, Nguyen Tran, Travis E Grotz, Fang-Shu Ou, Nabil Wasif, Jason Starr
Published: 202510.1200/PO-25-00492
Abstract
PURPOSE: Neoadjuvant immune checkpoint inhibitors (nICIs) have demonstrated high response rates in deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastroesophageal adenocarcinoma (GEA). The NEONIPIGA and INFINITY trials demonst…
Preview only. Read the full abstract at the source